Search company, investor...
Search
Liminal BioSciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

liminalbiosciences.com

Stage

IPO | IPO

Market Cap

0.54B

About Liminal BioSciences

Liminal Biosciences is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for patients suffering from diseases related to fibrosis. The company is advancing research in small molecules for a range of diseases related to fibrosis including respiratory, liver, and renal diseases. It is based in Laval, Quebec.

Liminal BioSciences Headquarters Location

440 Armand-Frappier Blvd Suite 300

Laval, Quebec,

Canada

450-781-0115

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Liminal BioSciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Liminal BioSciences is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Liminal BioSciences Patents

Liminal BioSciences has filed 10 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/9/2020

11/30/2021

Rare diseases, Monoclonal antibodies, Clusters of differentiation, Transcription factors, G protein coupled receptors

Grant

Application Date

4/9/2020

Grant Date

11/30/2021

Title

Related Topics

Rare diseases, Monoclonal antibodies, Clusters of differentiation, Transcription factors, G protein coupled receptors

Status

Grant

Latest Liminal BioSciences News

Liminal transfers to Nasdaq Capital Market, gets more time to comply with listing rule

Sep 2, 2022

Massimo Giachetti Liminal BioSciences (NASDAQ: LMNL ) received approval from the Qualifications Department of The Nasdaq Stock Market to transfer its common shares from the Nasdaq Global Market to the Nasdaq Capital Market. The Canadian company said its shares will begin trading on the Nasdaq Capital Market on Sept. 6 and will continue to trade under the symbol "LMNL". Liminal noted that in March 4, it received a notice from Nasdaq for not being in compliance with the exchange's minimum bid price rule of $1.00 per share for continued listing on the exchange. The company had then been granted 180 days to comply with the rule and now with the transfer to the Nasdaq Capital Market, Nasdaq has granted a second period of 180 calendar days or until Feb. 27, 2023, to regain compliance. Liminal said that it may implement a reverse stock split, if necessary, to regain compliance. Recommended For You

Liminal BioSciences Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Liminal BioSciences Rank

  • Where is Liminal BioSciences's headquarters?

    Liminal BioSciences's headquarters is located at 440 Armand-Frappier Blvd, Laval.

  • What is Liminal BioSciences's latest funding round?

    Liminal BioSciences's latest funding round is IPO.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.